XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies  
Schedule of the Company's net sales by medical indication

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

(In thousands)

​

September 30, 

​

Medical Indication

    

2020

    

2019

​

Analgesic

​

$

3,120

​

$

1,884

​

Anti-Psychosis

​

​

13,028

​

​

28,034

​

Cardiovascular

​

 

19,714

​

 

21,606

​

Central Nervous System

​

​

22,525

​

​

19,257

​

Endocrinology

​

​

3,233

​

​

—

​

Gastrointestinal

​

​

17,100

​

​

16,962

​

Infectious Disease

​

​

21,932

​

​

11,895

​

Migraine

​

 

9,690

​

 

9,143

​

Respiratory/Allergy/Cough/Cold

​

​

1,426

​

​

2,707

​

Urinary

​

​

1,458

​

​

435

​

Other

​

 

7,634

​

 

9,861

​

Contract manufacturing revenue

​

​

5,619

​

​

5,558

​

Total net sales

​

$

126,479

​

$

127,342

​

​

Summary of products which accounted for at least 10% of total net sales

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

​

​

September 30, 

​

​

​

    

2020

    

2019

    

​

Product 1

 

15

%

7

%

 

Product 2

 

9

%

20

%

 

​

Summary of customers which accounted for at least 10% of total net sales

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

​

    

September 30, 

    

    

​

    

2020

    

2019

    

​

Customer A

 

26

%

25

%

 

Customer B

 

22

%

27

%

 

Customer C

​

10

%

13

%

​